Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 7.6% - Should You Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s share price traded up 7.6% during trading on Wednesday . The stock traded as high as $0.26 and last traded at $0.26. 17,897,355 shares traded hands during trading, a decline of 70% from the average session volume of 59,221,816 shares. The stock had previously closed at $0.24.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a report on Friday, January 17th. They set a "hold" rating on the stock.

Tonix Pharmaceuticals Stock Up 24.3 %

The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The firm's fifty day moving average is $0.26 and its 200 day moving average is $0.29. The stock has a market cap of $55.51 million, a P/E ratio of -0.01 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. As a group, equities research analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned approximately 0.12% of Tonix Pharmaceuticals as of its most recent filing with the SEC. 82.26% of the stock is owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.